Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

dc.contributor.authorSævarsdóttir, Sædís
dc.contributor.authorStefansdottir, Lilja
dc.contributor.authorSulem, P.
dc.contributor.authorThorleifsson, G.
dc.contributor.authorFerkingstad, E.
dc.contributor.authorRutsdottir, G.
dc.contributor.authorGlintborg, B.
dc.contributor.authorWesterlind, H.
dc.contributor.authorGröndal, Gerður María
dc.contributor.authorLoft, I.C.
dc.contributor.authorSorensen, S.B.
dc.contributor.authorLie, B.A.
dc.contributor.authorBrink, M.
dc.contributor.authorArlestig, L.
dc.contributor.authorArnthorsson, A.O.
dc.contributor.authorBaecklund, E.
dc.contributor.authorBanasik, K.
dc.contributor.authorBank, S.
dc.contributor.authorBjorkman, L.I.
dc.contributor.authorEllingsen, T.
dc.contributor.authorErikstrup, C.
dc.contributor.authorFrei, O.
dc.contributor.authorGjertsson, I.
dc.contributor.authorGudbjartsson, D.F.
dc.contributor.authorGudjonsson, S.A.
dc.contributor.authorHalldorsson, G.H.
dc.contributor.authorHendricks, O.
dc.contributor.authorHillert, J.
dc.contributor.authorHogdall, E.
dc.contributor.authorJacobsen, Sø
dc.contributor.authorJensen, D.V.
dc.contributor.authorJonsson, Helgi
dc.contributor.authorKastbom, A.
dc.contributor.authorKockum, I.
dc.contributor.authorKristensen, S.
dc.contributor.authorKristjansdottir, Helga
dc.contributor.authorLarsen, M.H.
dc.contributor.authorLinauskas, A.
dc.contributor.authorHauge, E.-M.
dc.contributor.authorLoft, A.G.
dc.contributor.authorLúðvíksson, Björn Rúnar
dc.contributor.authorLund, S.H.
dc.contributor.authorMarkusson, Þorsteinn
dc.contributor.authorMasson, G.
dc.contributor.authorMelsted, P.
dc.contributor.authorMoore, K.H.S.
dc.contributor.authorMunk, H.
dc.contributor.authorNielsen, K.R.
dc.contributor.authorNorddahl, G.L.
dc.contributor.authorOddsson, A.
dc.contributor.authorOlafsdottir, T.A.
dc.contributor.authorOlason, P.I.
dc.contributor.authorOlsson, T.
dc.contributor.authorOstrowski, S.R.
dc.contributor.authorHørslev-Petersen, K.
dc.contributor.authorRognvaldsson, S.
dc.contributor.authorSanner, H.
dc.contributor.authorSilberberg, G.N.
dc.contributor.authorStefansson, H.
dc.contributor.authorSørensen, E.
dc.contributor.authorSørensen, I.J.
dc.contributor.authorTuresson, C.
dc.contributor.authorBergman, T.
dc.contributor.authorAlfredsson, L.
dc.contributor.authorKvien, T.K.
dc.contributor.authorBrunak, Sø
dc.contributor.authorSteinsson, K.
dc.contributor.authorAndersen, V.
dc.contributor.authorAndreassen, O.A.
dc.contributor.authorRantapää-Dahlqvist, S.
dc.contributor.authorHetland, M.L.
dc.contributor.authorKlareskog, L.
dc.contributor.authorAskling, J.
dc.contributor.authorPadyukov, L.
dc.contributor.authorPedersen, O.B.V.
dc.contributor.authorThorsteinsdottir, U.
dc.contributor.authorJonsdottir, I.
dc.contributor.authorStefánsson, Kári
dc.contributor.departmentFaculty of Medicine
dc.contributor.departmentFaculty of Industrial Engineering, Mechanical Engineering and Computer Science
dc.contributor.departmentFaculty of Physical Sciences
dc.contributor.schoolHealth Sciences
dc.date.accessioned2025-11-20T08:59:02Z
dc.date.available2025-11-20T08:59:02Z
dc.date.issued2022-04-25
dc.descriptionFunding Information: Funding The study was funded by NORDFORSK (grant agreement no. 90825, project NORA), the Swedish Research Council (2018-02803), the Swedish innovation Agency (Vinnova), Innovationsfonden and The Research Council of Norway, Region Stockholm-Karolinska Institutet and Region Västerbotten (ALF), the Danish Rheumatism Association (R194-A6956), the Swedish Brain Foundation, Nils and Bibbi Jensens Foundation, the Knut and Alice Wallenberg Foundation, Margaretha af Ugglas Foundation, the South-Eastern Heath Region of Norway, the Health Research Fund of Central Denmark Region, Region of Southern Denmark, the A.P. Moller Foundation for the Advancement of Medical Science, the Colitis-Crohn Foreningen, the Novo Nordisk Foundation (NNF15OC0016932), Aase og Ejnar Danielsens Fond, Beckett-Fonden, Augustinus Fonden, Knud and Edith Eriksens Mindefond, Laege Sofus Carl Emil Friis and Hustru Olga Doris Friis’ Legat, the Psoriasis Forskningsfonden, the University of Aarhus, the Danish Rheumatism Association (R194-A6956, A1923, A3037 and A3570 – www. gigtforeningen.dk), Region of Southern Denmark’s PhD Fund, 12/7725 (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital. dk). MoBa Genetics has been funded by the Research Council of Norway (#229624, #223273), South East and Western Norway Health Authorities, ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Novo Nordisk Foundation and the University of Bergen. KB and SB acknowledge the Novo Nordisk Foundation (grant NNF14CC0001). Funding Information: competing financial interests as employees. OAA is a consultant to HealthLytix. The following coauthors report the following but unrelated to the current report: Karolinska Institutet, with JA as principal investigator, has entered into agreements with the following entities, mainly but not exclusively for safety monitoring of rheumatology immunomodulators: Abbvie, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis and Sanofi, unrelated to the present study. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board memberships in Proscion A/S and Intomics A/S. BG has received research grants from AbbVie, Bristol Myers-Squibb and Pfizer; OH has received research grants from AbbVie, Novartis and Pfizer, DVJ has received speaker and consultation fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, AGL has received speaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; and CT has received consulting fees from Roche, speaker fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Publisher Copyright: © Funding Information: Funding The study was funded by NORDFORSK (grant agreement no. 90825, project NORA), the Swedish Research Council (2018-02803), the Swedish innovation Agency (Vinnova), Innovationsfonden and The Research Council of Norway, Region Stockholm-Karolinska Institutet and Region Västerbotten (ALF), the Danish Rheumatism Association (R194-A6956), the Swedish Brain Foundation, Nils and Bibbi Jensens Foundation, the Knut and Alice Wallenberg Foundation, Margaretha af Ugglas Foundation, the South-Eastern Heath Region of Norway, the Health Research Fund of Central Denmark Region, Region of Southern Denmark, the A.P. Moller Foundation for the Advancement of Medical Science, the Colitis-Crohn Foreningen, the Novo Nordisk Foundation (NNF15OC0016932), Aase og Ejnar Danielsens Fond, Beckett-Fonden, Augustinus Fonden, Knud and Edith Eriksens Mindefond, Laege Sofus Carl Emil Friis and Hustru Olga Doris Friis’ Legat, the Psoriasis Forskningsfonden, the University of Aarhus, the Danish Rheumatism Association (R194-A6956, A1923, A3037 and A3570 – www. gigtforeningen.dk), Region of Southern Denmark’s PhD Fund, 12/7725 (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital. dk). MoBa Genetics has been funded by the Research Council of Norway (#229624, #223273), South East and Western Norway Health Authorities, ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Novo Nordisk Foundation and the University of Bergen. KB and SB acknowledge the Novo Nordisk Foundation (grant NNF14CC0001). Funding Information: competing financial interests as employees. OAA is a consultant to HealthLytix. The following coauthors report the following but unrelated to the current report: Karolinska Institutet, with JA as principal investigator, has entered into agreements with the following entities, mainly but not exclusively for safety monitoring of rheumatology immunomodulators: Abbvie, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis and Sanofi, unrelated to the present study. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board memberships in Proscion A/S and Intomics A/S. BG has received research grants from AbbVie, Bristol Myers-Squibb and Pfizer; OH has received research grants from AbbVie, Novartis and Pfizer, DVJ has received speaker and consultation fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, AGL has received speaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; and CT has received consulting fees from Roche, speaker fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Publisher Copyright: ©en
dc.description.abstractObjectives To find causal genes for rheumatoid arthritis (RA) and its seropositive (RF and/or ACPA positive) and seronegative subsets. Methods We performed a genome-wide association study (GWAS) of 31 313 RA cases (68% seropositive) and ∼1 million controls from Northwestern Europe. We searched for causal genes outside the HLA-locus through effect on coding, mRNA expression in several tissues and/or levels of plasma proteins (SomaScan) and did network analysis (Qiagen). Results We found 25 sequence variants for RA overall, 33 for seropositive and 2 for seronegative RA, altogether 37 sequence variants at 34 non-HLA loci, of which 15 are novel. Genomic, transcriptomic and proteomic analysis of these yielded 25 causal genes in seropositive RA and additional two overall. Most encode proteins in the network of interferon-Alpha/beta and IL-12/23 that signal through the JAK/STAT-pathway. Highlighting those with largest effect on seropositive RA, a rare missense variant in STAT4 (rs140675301-A) that is independent of reported non-coding STAT4-variants, increases the risk of seropositive RA 2.27-fold (p=2.1×10-9), more than the rs2476601-A missense variant in PTPN22 (OR=1.59, p=1.3×10-160). STAT4 rs140675301-A replaces hydrophilic glutamic acid with hydrophobic valine (Glu128Val) in a conserved, surface-exposed loop. A stop-mutation (rs76428106-C) in FLT3 increases seropositive RA risk (OR=1.35, p=6.6×10-11). Independent missense variants in TYK2 (rs34536443-C, rs12720356-C, rs35018800-A, latter two novel) associate with decreased risk of seropositive RA (ORs=0.63-0.87, p=10-9-10-27) and decreased plasma levels of interferon-Alpha/beta receptor 1 that signals through TYK2/JAK1/STAT4. Conclusion Sequence variants pointing to causal genes in the JAK/STAT pathway have largest effect on seropositive RA, while associations with seronegative RA remain scarce.en
dc.description.versionPeer revieweden
dc.format.extent11
dc.format.extent1576361
dc.format.extent1085-1095
dc.identifier.citationSævarsdóttir, S, Stefansdottir, L, Sulem, P, Thorleifsson, G, Ferkingstad, E, Rutsdottir, G, Glintborg, B, Westerlind, H, Gröndal, G M, Loft, I C, Sorensen, S B, Lie, B A, Brink, M, Arlestig, L, Arnthorsson, A O, Baecklund, E, Banasik, K, Bank, S, Bjorkman, L I, Ellingsen, T, Erikstrup, C, Frei, O, Gjertsson, I, Gudbjartsson, D F, Gudjonsson, S A, Halldorsson, G H, Hendricks, O, Hillert, J, Hogdall, E, Jacobsen, S, Jensen, D V, Jonsson, H, Kastbom, A, Kockum, I, Kristensen, S, Kristjansdottir, H, Larsen, M H, Linauskas, A, Hauge, E-M, Loft, A G, Lúðvíksson, B R, Lund, S H, Markusson, Þ, Masson, G, Melsted, P, Moore, K H S, Munk, H, Nielsen, K R, Norddahl, G L, Oddsson, A, Olafsdottir, T A, Olason, P I, Olsson, T, Ostrowski, S R, Hørslev-Petersen, K, Rognvaldsson, S, Sanner, H, Silberberg, G N, Stefansson, H, Sørensen, E, Sørensen, I J, Turesson, C, Bergman, T, Alfredsson, L, Kvien, T K, Brunak, S, Steinsson, K, Andersen, V, Andreassen, O A, Rantapää-Dahlqvist, S, Hetland, M L, Klareskog, L, Askling, J, Padyukov, L, Pedersen, O B V, Thorsteinsdottir, U, Jonsdottir, I & Stefánsson, K 2022, 'Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset', Annals of the rheumatic diseases., vol. 81, no. 8, pp. 1085-1095. https://doi.org/10.1136/annrheumdis-2021-221754en
dc.identifier.doi10.1136/annrheumdis-2021-221754
dc.identifier.issn0003-4967
dc.identifier.other67897902
dc.identifier.other9b60aa11-85a4-4bf8-ae8a-98ccbae07669
dc.identifier.otherORCID: /0000-0002-3806-2296/work/123415657
dc.identifier.other85130778612
dc.identifier.other35470158
dc.identifier.otherunpaywall: 10.1136/annrheumdis-2021-221754
dc.identifier.urihttps://hdl.handle.net/20.500.11815/6940
dc.language.isoen
dc.relation.ispartofseriesAnnals of the rheumatic diseases.; 81(8)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85130778612en
dc.relation.urlhttps://www.scopus.com/pages/publications/85130778612en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectautoantibodiesen
dc.subjectpolymorphism, geneticen
dc.subjectrheumatoid arthritisen
dc.subjectGenome-Wide Association Studyen
dc.subjectProtein Tyrosine Phosphatase, Non-Receptor Type 22/geneticsen
dc.subjectInterferon-alphaen
dc.subjectHumansen
dc.subjectSignal Transduction/geneticsen
dc.subjectArthritis, Rheumatoid/geneticsen
dc.subjectGenetic Predisposition to Disease/geneticsen
dc.subjectJanus Kinases/geneticsen
dc.subjectProteomicsen
dc.subjectSTAT Transcription Factors/geneticsen
dc.subjectGeneral Biochemistry,Genetics and Molecular Biologyen
dc.subjectRheumatologyen
dc.subjectImmunology and Allergyen
dc.subjectImmunologyen
dc.titleMultiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subseten
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
1085.full.pdf
Stærð:
1.5 MB
Snið:
Adobe Portable Document Format

Undirflokkur